Magnetic Nanoparticles Leap From Lab Bench to Breast Cancer Clinical Trials

NEW YORK--()--Manhattan Scientifics, Inc. (MHTX) (OTCQB: MHTX) today issued an update on its affiliates' progress regarding its Early Cancer Detection Diagnostic

The entire article can be read at this link:

Manhattan Scientifics seed funded Imagion Biosystems. MHTX invested eight years of development and owns 64 million shares of Imagion Biosystems after its public offering on the Australian stock exchange. (IBX.ASX)

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. ( is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.


Manhattan Scientifics Inc.
Manny Tsoupanarias, CEO, 917-688-4158

Recent Stories

RSS feed for Manhattan Scientifics Inc.

Manhattan Scientifics Inc.